Search Results 721-730 of 17420 for alopecia

1. Mayo Clinic

   Sections. Products and services. The Mayo Clinic Diet: What is your weight-loss goal? 5-10 · Share · Tweet . IMG-20403546. Home; NAFLD_Spectrum_Sm.

2. Carboplatin and Gemcitabine Hydrochloride With or Without VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   ... alopecia. Patients with treatment related effects, such as peripheral neuropathy, that are grade 1 or less are eligible. Prior exposure to gemcitabine ...

3. Mayo Clinic

   ... . IMG-20423117. Home; oncology-therapy-car-t-4col-3712678-0029. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled ...

4. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

   Residual CTCAE ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy. Known history of HIV ...

5. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

   ... alopecia; Radiation therapy within ≤ 14 days; Active or untreated brain metastases; History of carcinomatous meningitis; Uncontrolled concurrent malignancy ...

6. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...

7. Health Topics - Mayo Clinic News Network

   Traveler's diarrhea is a common and uncomfortable digestive tract disorder that can affect people when they travel to new environments.

8. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

   current) related to prior anticancer therapy (excluding alopecia, lymphopenia, peripheral neuropathy, and ototoxicity, which are excluded only if ≥ Grade 3) ...

9. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

   Alopecia; Neuropathy resolved to ≤ Grade 2; Congestive heart failure that was ≤ Grade 1 in severity at the time of occurrence and resolved completely. Has ...

10. Mayo Clinic

    ... . IMG-20451438. Home; cc-man-bedtime-with-laptop_thumbnail. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled in ...